ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial

ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial

305381

ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial

  An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative treatment, however, stopped in June 2020, after a comprehensive analysis of INROADS (NCT03436199) data showed that walking speed gains achieved in about 20% of trial participants were…

You must be logged in to read/download the full post.